Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Pass Above 50-Day Moving Average – Should You Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $4.36 and traded as high as $4.63. Galmed Pharmaceuticals shares last traded at $4.63, with a volume of 302,067 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Galmed Pharmaceuticals Trading Down 0.9%

The business has a 50 day moving average of $4.36 and a two-hundred day moving average of $4.72. The firm has a market cap of $4.78 million, a P/E ratio of -0.30 and a beta of 0.67.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) EPS for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.14% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.